Disposition of betamethasone in parturient women after intramuscular administration.

MC Petersen, JJ Ashley, WG McBride, RL Nation

Research output: Contribution to journalArticleResearchpeer-review

Abstract

When betamethasone phosphate equivalent to 8 mg betamethasone was administered intramuscularly in solution (Celestone Injection) to pregnant women, a large proportion of this ester was absorbed unchanged. Bioavailability of betamethasone from the phosphate ester was as high as after intravenous injection. When pregnant patients received the equivalent of either 6 or 12 mg betamethasone in a formulation containing 3.1 mg/ml betamethasone acetate suspended in a solution of 4 mg/ml betamethasone phosphate (Celestone Chronodose), much of the phosphate ester was absorbed intact but betamethasone acetate was not detected in plasma. Availability of betamethasone from Celestone Chronodose was much lower than from Celestone Injection. After administration of either formulation, maternal plasma cortisol concentrations fell towards a basal level but were rising again within 2 to 3 days of the last dose. We conclude that Celestone Chronodose does not provide prolonged release of betamethasone and offers no advantage over Celestone Injection. 1984 The British Pharmacological Society

Original languageEnglish
Pages (from-to)383-392
Number of pages10
JournalBritish Journal of Clinical Pharmacology
Volume18
Issue number3
DOIs
Publication statusPublished - 1 Jan 1984

Cite this

@article{2ddf98bca7d041758d66410b1fccf173,
title = "Disposition of betamethasone in parturient women after intramuscular administration.",
abstract = "When betamethasone phosphate equivalent to 8 mg betamethasone was administered intramuscularly in solution (Celestone Injection) to pregnant women, a large proportion of this ester was absorbed unchanged. Bioavailability of betamethasone from the phosphate ester was as high as after intravenous injection. When pregnant patients received the equivalent of either 6 or 12 mg betamethasone in a formulation containing 3.1 mg/ml betamethasone acetate suspended in a solution of 4 mg/ml betamethasone phosphate (Celestone Chronodose), much of the phosphate ester was absorbed intact but betamethasone acetate was not detected in plasma. Availability of betamethasone from Celestone Chronodose was much lower than from Celestone Injection. After administration of either formulation, maternal plasma cortisol concentrations fell towards a basal level but were rising again within 2 to 3 days of the last dose. We conclude that Celestone Chronodose does not provide prolonged release of betamethasone and offers no advantage over Celestone Injection. 1984 The British Pharmacological Society",
author = "MC Petersen and JJ Ashley and WG McBride and RL Nation",
year = "1984",
month = "1",
day = "1",
doi = "10.1111/j.1365-2125.1984.tb02480.x",
language = "English",
volume = "18",
pages = "383--392",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "3",

}

Disposition of betamethasone in parturient women after intramuscular administration. / Petersen, MC; Ashley, JJ; McBride, WG; Nation, RL.

In: British Journal of Clinical Pharmacology, Vol. 18, No. 3, 01.01.1984, p. 383-392.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Disposition of betamethasone in parturient women after intramuscular administration.

AU - Petersen, MC

AU - Ashley, JJ

AU - McBride, WG

AU - Nation, RL

PY - 1984/1/1

Y1 - 1984/1/1

N2 - When betamethasone phosphate equivalent to 8 mg betamethasone was administered intramuscularly in solution (Celestone Injection) to pregnant women, a large proportion of this ester was absorbed unchanged. Bioavailability of betamethasone from the phosphate ester was as high as after intravenous injection. When pregnant patients received the equivalent of either 6 or 12 mg betamethasone in a formulation containing 3.1 mg/ml betamethasone acetate suspended in a solution of 4 mg/ml betamethasone phosphate (Celestone Chronodose), much of the phosphate ester was absorbed intact but betamethasone acetate was not detected in plasma. Availability of betamethasone from Celestone Chronodose was much lower than from Celestone Injection. After administration of either formulation, maternal plasma cortisol concentrations fell towards a basal level but were rising again within 2 to 3 days of the last dose. We conclude that Celestone Chronodose does not provide prolonged release of betamethasone and offers no advantage over Celestone Injection. 1984 The British Pharmacological Society

AB - When betamethasone phosphate equivalent to 8 mg betamethasone was administered intramuscularly in solution (Celestone Injection) to pregnant women, a large proportion of this ester was absorbed unchanged. Bioavailability of betamethasone from the phosphate ester was as high as after intravenous injection. When pregnant patients received the equivalent of either 6 or 12 mg betamethasone in a formulation containing 3.1 mg/ml betamethasone acetate suspended in a solution of 4 mg/ml betamethasone phosphate (Celestone Chronodose), much of the phosphate ester was absorbed intact but betamethasone acetate was not detected in plasma. Availability of betamethasone from Celestone Chronodose was much lower than from Celestone Injection. After administration of either formulation, maternal plasma cortisol concentrations fell towards a basal level but were rising again within 2 to 3 days of the last dose. We conclude that Celestone Chronodose does not provide prolonged release of betamethasone and offers no advantage over Celestone Injection. 1984 The British Pharmacological Society

UR - http://www.scopus.com/inward/record.url?scp=0021222529&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2125.1984.tb02480.x

DO - 10.1111/j.1365-2125.1984.tb02480.x

M3 - Article

VL - 18

SP - 383

EP - 392

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 3

ER -